Experimental combo targets rare lymphoma in early trial

NCT ID NCT07278856

Recruiting now Disease control Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 1 trial is testing whether adding the drug ruxolitinib to standard CHOP chemotherapy is safe and effective for people with untreated nodal T-follicular helper (TFH) cell lymphoma, a rare type of non-Hodgkin lymphoma. About 20 adults will receive the combination to find the best dose and check for side effects. The goal is to see if this approach can improve outcomes for this hard-to-treat cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ruxolitinib combined with CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone)
What this could lead to: If successful, this could lead to a more effective first treatment for a rare type of lymphoma, potentially improving remission rates.
What could go wrong: This is a very early phase 1 trial with only 20 participants, so safety and dosing are the main focus. The combination may cause significant side effects, and it is too soon to know if it works better than standard therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FOLLICULAR HELPER T-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

angioimmunoblastic T-cell lymphoma mature T-cell and NK-cell non-Hodgkin lymphoma Nodal T-follicular helper cell lymphoma, follicular type peripheral T-cell lymphoma, not otherwise specified T-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FOLLICULAR HELPER T-CELL LYMPHOMA FOLLICULAR HELPER T-CELL LYMPHOMA, ANGIOIMMUNOBLASTIC-TYPE FOLLICULAR HELPER T-CELL LYMPHOMA, FOLLICULAR-TYPE FOLLICULAR HELPER T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED MATURE T-CELL AND NK-CELL NON-HODGKIN LYMPHOMA PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED

Contacts and locations

Locations

City of Hope Medical Center
RECRUITING

Duarte, California, 91010, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.